Drug Profile


Alternative Names: Cenersen sodium; EL625; EL831; OL(1)p53

Latest Information Update: 28 Oct 2014

Price : $50

At a glance

  • Originator University of Nebraska Medical Center
  • Developer Eleos; H. Lee Moffitt Cancer Center and Research Institute
  • Class Antineoplastics; Antisense oligonucleotides
  • Mechanism of Action Tumour suppressor protein p53 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia; Acute myeloid leukaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Myelodysplastic syndromes
  • Discontinued Acute myeloid leukaemia; Chronic lymphocytic leukaemia

Most Recent Events

  • 01 Sep 2014 Phase-I clinical trials in Myelodysplastic syndromes in USA (IV)
  • 18 Jul 2012 Discontinued - Phase-II for Acute myeloid leukaemia in USA (IV)
  • 18 Jul 2012 Discontinued - Phase-II for Chronic lymphocytic leukaemia in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top